Amer Zeidan, MD

Articles by Amer Zeidan, MD

Utilization Impacts of New Oral Substitutes for Parenteral Cancer-Related Therapies

ByAmy J. Davidoff, PhD,Amer Zeidan, MD,Franklin Hendrick, BS,Bruce C. Stuart, PhD,Vu H. Duong, MD, MS,Maria R. Baer, MD,Rahul A. Shenolikar, PhD,Steven D. Gore, MD

March 17th 2015

Examination of changes in utilization, dose adequacy, and duration associated with market entry of the oral chelator deferasirox as a potential substitute for parenteral deferoxamine.

Latest Updated Articles

Utilization Impacts of New Oral Substitutes for Parenteral Cancer-Related Therapies
Published: March 17th 2015 | Updated:

Amer Zeidan, MD

Articles by Amer Zeidan, MD

Utilization Impacts of New Oral Substitutes for Parenteral Cancer-Related Therapies

Latest Updated Articles

Trending on Pharmacy Times

Combination of Olezarsen and Fibrates Yields Enhanced Triglyceride Reduction

Influenza Hospitalizations in Children Reveal Significant Non-respiratory Complications

FDA Approves Aflibercept Injection to Treat Patients With Macular Edema Following RVO